Key result
IV alteplase linked to ~7-point median NIHSS reduction at 24 hours in acute ischemic stroke.
Why the study?
The safety and efficacy of intravenous alteplase in patients with acute ischemic stroke and its associated clinical and functional outcomes in a limited-resource setting were not well characterized.
Does intravenous alteplase improve neurological outcomes in adults with acute ischemic stroke?
Observational (n=48)
No
Does intravenous alteplase improve neurological outcomes in adults with acute ischemic stroke?
p-value: p=<0.0001
Intravenous alteplase administration in acute ischemic stroke yields early neurological improvement and acceptable safety outcomes even in resource-limited tertiary care settings.
Objective:To evaluate the safety and efficacy of intravenous (IV) alteplase in patients with acute ischemic stroke (AIS) and to assess the clinical and functional outcomes, time intervals and any complications associated with the treatment.Methods:This observational retrospective study was conducted at Mukhtar A. Sheikh Hospital, Pakistanfrom January 2025 to December 2025. Patients aged ≥ 18 years old with AIS were included. Only patients who were treated with IV alteplase in a specific time window were included. Data was collected and analyzed using SPSS. The stroke severity was measured as NIHSS scores. Continuous outcomes were expressed as medians. Frequencies were used to express categorical variables. Mann Whitney U test and chi square test were used to determinethe incidence of favorable functional outcomes among different categories. Results:The study included 48 participants. The median age was 62 years(50 –68.25). The baseline NIHSS score was 13 (10-17.75). The symptom onset to arrival time was 150 (120-180) mins. The NIHSS score significantly improved over time (p<0.0001). The functional outcome at 3 months was favourablefor 37(77.1%). The functional outcomes were significantly associated with age (p=0.032).Conclusion:The IV administration of alteplase was associated with increased early neurological improvementand good safety outcomes.
No takes yet. Share an insight, caveat, or question.
Farid et al. (2026) conducted an observational in Acute Ischemic Stroke (n=48). Intravenous Alteplase was evaluated on Neurological improvement as measured by the change in median NIHSS score from baseline to 24 hours (p=<0.0001). Intravenous alteplase administration in patients with acute ischemic stroke was associated with significant early neurological improvement, with median NIHSS scores decreasing from 13 at baseline to 6 at 24 hours (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: